SiriusXM Reports First Quarter 2025 Operating and Financial Results
NEW YORK, May 1, 2025 /PRNewswire/ — SiriusXM (NASDAQ: SIRI) today reported its operating and financial results for the first quarter of 2025. The full earnings... Read more.
Identiv and InPlay Introduce Next-Generation BLE-Enabled Smart Labels for Industrial IoT Applications
Companies collaborate to develop high-performance, scalable BLE smart label portfolio for cold chain, logistics, and healthcare applications SANTA ANA, Calif. ,... Read more.
WILDBRAIN ANNOUNCES CONFERENCE CALL FOR ITS FISCAL 2025 Q3 FINANCIAL RESULTS
TORONTO, May 1, 2025 /PRNewswire/ – WildBrain Ltd. (“WildBrain” or the “Company“) (TSX: WILD), a global leader in kids’ and... Read more.
Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02
Phase 1b/2a diSArm trial evaluated AP-SA02 as a potential treatment for complicated Staphylococcus aureus bacteremia Topline data anticipated in Q2 2025 to support... Read more.
Scinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin Diseases
The webinar will explore PC111, a novel monoclonal antibody drug candidate with the potential to transform the treatment landscape for Pemphigus Vulgaris and Stevens-Johnson... Read more.
STREAM SYSTEMS APPOINTS MARK WEBSTER CHIEF EXECUTIVE OFFICER
NEW YORK, May 1, 2025 /PRNewswire/ — Stream Systems LLC has appointed Mark Webster as its new Chief Executive Officer, effective April 28, 2025. Webster assumes... Read more.
BDR announces Profit Launch business planning workshops for home service companies
Upcoming sessions will help HVAC, plumbing, electrical, and other contracting companies developcomprehensive business plans SEATTLE, May 1, 2025 /PRNewswire/ — Business... Read more.
Alkermes plc Reports First Quarter 2025 Financial Results
— First Quarter Revenues of $306.5 Million — — GAAP Net Income of $22.5 Million and Diluted GAAP Earnings per Share of $0.13 — — Company... Read more.
Blueprint Medicines Reports First Quarter 2025 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
— Achieved 61% year-over-year growth with $149.4 million in AYVAKIT net product revenues in the first quarter 2025 — — Raising AYVAKIT net product... Read more.
Data from First-in-Human Trial targeting CISH, a Novel Immune Checkpoint, in Patients with Metastatic Colorectal Cancer Presented at 2025 American Association for Cancer Research (AACR) Annual Meeting
Study Administered CRISPR genetically engineered CISH-knockout Tumor Infiltrating Lymphocytes as a Model System to Evaluate the Safety and Efficacy of this Classically... Read more.